Rallybio Corporation
NASDAQ:RLYB
1.13 (USD) • At close September 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Rallybio Corporation |
Symbool | RLYB |
Munteenheid | USD |
Prijs | 1.13 |
Beurswaarde | 46,880,988 |
Dividendpercentage | 0% |
52-weken bereik | 1.08 - 5.15 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Stephen Uden M.B, M.D. |
Website | https://www.rallybio.com |
An error occurred while fetching data.
Over Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)